Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Brainstorm Cell Therapeutics Inc. (BCLI) had Cash Flow from Financial Activities of $5.79M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-2.90M |
|
-- |
|
-- |
|
$2.57M |
|
$-2.57M |
|
$-0.33M |
|
$-2.90M |
|
$-2.90M |
|
$-2.90M |
|
$-2.90M |
|
$-2.90M |
|
$-2.90M |
|
$-2.57M |
|
$-2.52M |
|
8.62M |
|
8.62M |
|
$-0.34 |
|
$-0.34 |
|
| Balance Sheet Financials | |
$1.51M |
|
$0.33M |
|
$1.05M |
|
$2.57M |
|
$8.53M |
|
-- |
|
$0.10M |
|
$8.62M |
|
$-6.06M |
|
$-6.06M |
|
$-6.06M |
|
10.12M |
|
| Cash Flow Statement Financials | |
$-5.13M |
|
$0.00M |
|
|
Cash Flow from Financial Activities |
$5.79M |
$0.37M |
|
$1.02M |
|
$0.65M |
|
$1.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.18 |
|
-- |
|
-- |
|
-- |
|
-0.02 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.13M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
47.93% |
|
47.93% |
|
-113.13% |
|
47.93% |
|
$-0.60 |
|
$-0.60 |
|
$-0.60 |
|